EINDHOVEN, the Netherlands, May 15, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal …
Venlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an updated version of its clinical decision support platform, QIAGEN Clinical Insight Interpret for NGS molecular profiling of …
De Personal Medicine DNA test van MijnMedicijn is met 34 genen de meest uitgebreide farmacogenetische DNA test in Europa. APELDOORN, GELDERLAND, NEDERLAND, May 14, 2024 /EINPresswire.com/ -- De Personal Medicine DNA-test van MijnMedicijn gaat verder dan …
Amsterdam and Kyiv, 14 May 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, is pleased to share that VEON’s 100%-owned subsidiary Kyivstar, has been named the top …
Amsterdam and Islamabad, 14 May 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that Tamasha, its leading digital entertainment platform in Pakistan, …
• Petosemtamab erhielt die BTD für die Behandlung von bereits behandeltem HNSCC UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, May 14, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen aus dem Bereich der klinischen Onkologie, das …
• Le pétosemtamab obtient le statut de thérapie innovante pour le traitement d’un carcinome épidermoïde de la tête et du cou (CETC) précédemment traité UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 14 mai 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : …
Leapmotor International Begins Operations to Expand Global Electric Vehicle Sales Starting September 2024 in Nine European Countries, Followed by Other Key Growth Regions Leapmotor International, a 51/49 Stellantis-led company between Stellantis and …
Progress on share buyback programme ING announced today that, as part of our €2.5 billion share buyback programme announced on 2 May 2024, the company repurchased 21,801,401 shares during the week of 6 May 2024 up to and including 10 May 2024. The shares …
AccuKnox Partners with SparkSupport to Deliver Zero Trust CNAPP (Cloud Native Application Protection Platform) to Tible MENLO PARK, CA, UNITED STATES, May 13, 2024 /EINPresswire.com/ -- AccuKnox Partners with SparkSupport to Deliver Zero Trust CNAPP ( …
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length …
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the …
Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Plus …
Ithraa Alkhair Hosts First Seminar with Belgian and Dutch Pilgrims in Preparation for Hajj 1445H ANTWERP, BELGIUM, May 11, 2024 /EINPresswire.com/ -- Ithraa Alkhair Company for Pilgrims Services, a licensed provider of Hajj services for non-Arab African …
Petosemtamab in Kombination mit Pembrolizumab bei 1L (Erstlinientherapie) HNSCC – erste vorläufige klinische Daten auf der ASCO-Jahrestagung 2024; Vorbereitung einer möglichen Phase-III-Studie Zeno-BLA zur vorrangigen Prüfung durch die FDA für die …
Données cliniques intermédiaires initiales concernant le pétosemtamab en association avec le pembrolizumab en traitement de 1re ligne du CETC présentées lors du congrès annuel de l’ASCO 2024 ; éventuel essai de phase III en préparation Examen prioritaire …
SCHLIEREN, ZURICH, SWITZERLAND, May 9, 2024 /EINPresswire.com/ -- Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced the nomination of an anti-allergen multispecific …
AST Announces IP3 2024, a Collaborative Fixed-Price, Fixed-Term Patent Purchase and Licensing Program connecting patent sellers with top High Tech companies PRINCETON, NJ, USA, May 9, 2024 /EINPresswire.com/ -- AST is excited to announce the upcoming …
"eFirst 2.0" covers the basics of electronic evidence and criminal phenomena related to new technologies for EU Law Enforcement first responders BRUSSELS, BELGIUM, May 9, 2024 /EINPresswire.com/ -- Thanks to funding from the European …
-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first patients in TANDEM, pivotal Phase 3 trial …
